Transmedics Group Inc [TMDX] stock prices are up 6.59% to $128.5 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TMDX shares have gain 22.10% over the last week, with a monthly amount drifted -0.53%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on December 17, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $75 from $116. Previously, Needham downgraded its rating to Hold on November 22, 2024. On October 29, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $125 on the stock. Needham reiterated its Buy rating and decreased its price target to $109 on October 29, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $200 as its price target on September 24, 2024. Needham started tracking with a Buy rating for this stock on August 21, 2024, and assigned it a price target of $208. In a note dated June 06, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $161 on this stock.
The stock price of Transmedics Group Inc [TMDX] has been fluctuating between $55.00 and $177.37 over the past year. Currently, Wall Street analysts expect the stock to reach $111.75 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $128.5 at the most recent close of the market. An investor can expect a potential drop of -13.04% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
The Transmedics Group Inc [NASDAQ:TMDX] reported sales of 531.29M for trailing twelve months, representing a surge of 37.68%. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.28 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Transmedics Group Inc [NASDAQ:TMDX]’s Current Ratio is 9.86. As well, the Quick Ratio is 9.17, while the Cash Ratio is 7.07. Considering the valuation of this stock, the price to sales ratio is 8.25, the price to book ratio is 13.75 and price to earnings (TTM) ratio is 66.45.
Transactions by insiders
Recent insider trading involved EDWARD BASILE, Director, that happened on Aug 04 ’25 when 4143.0 shares were purchased. Ranganath Anil P. completed a deal on Jun 09 ’25 to sell 686.0 shares. Meanwhile, Director Basile Edward M sold 5000.0 shares on May 27 ’25.
